Fore Biotherapeutics: Funding, Investors & Team (Sep 2026)
Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics. The company is creating a pipeline of precision oncology treatments aimed at patients with unaddressed mutations across well-established oncology targets.
Fore Biotherapeutics has raised $142M across 2 funding rounds on record, the most recent a Series D of $67.4M announced in Jul 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Fore Biotherapeutics Company Profile and Key Stats
Latest funding round on record: Jul 2026.
Fore Biotherapeutics Funding Rounds
Fore Biotherapeutics raised $75.0M in a Series D announced in Aug 2023.
2.9 years later, a Series D of $67.4M was announced in Jul 2026.
Fore Biotherapeutics Investors
20 investors are recorded in total; the 5 named above are those the record identifies.
Fore Biotherapeutics Founders and Leadership Team
Contact details for the Fore Biotherapeutics team: 1 of 3 have an email address on file.
Start 14-day free trial →Fore Biotherapeutics Funding Compared to Other Biotechnology Startups
Fore Biotherapeutics' latest round of $67.4M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Fore Biotherapeutics in Biotechnology and Philadelphia
Companies Similar to Fore Biotherapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Fore Biotherapeutics Funding FAQs
What does Fore Biotherapeutics do?
Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics. The company is creating a pipeline of precision oncology treatments aimed at patients with unaddressed mutations across well-established oncology targets.
How much funding has Fore Biotherapeutics raised?
Fore Biotherapeutics has raised $142M across 2 rounds on record. The most recent is a Series D of $67.4M announced in Jul 2026.
When did Fore Biotherapeutics last raise funding?
Fore Biotherapeutics' most recent funding round on record is a Series D of $67.4M, announced in Jul 2026.
Who has invested in Fore Biotherapeutics?
Investors on record for Fore Biotherapeutics include Wellington Management, Cormorant Asset Management, OrbiMed, SR One, Medicxi. FundedIQ records 20 investors in total.
Who founded Fore Biotherapeutics?
FundedIQ lists Michael (Founder & CEO) at Fore Biotherapeutics.
Who is the CEO of Fore Biotherapeutics?
William is listed as Chief Executive Officer at Fore Biotherapeutics.
Where is Fore Biotherapeutics headquartered?
Fore Biotherapeutics is based in Philadelphia, Pennsylvania, United States.
How many employees does Fore Biotherapeutics have?
Fore Biotherapeutics is in the 11-50 employee band.
When was Fore Biotherapeutics founded?
Fore Biotherapeutics was founded in 2011.
How does Fore Biotherapeutics' funding compare to other Biotechnology startups?
Fore Biotherapeutics' latest round of $67.4M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Fore Biotherapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Fore Biotherapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.